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BACKGROUND 
Abuse of drug remains a serious health and social problem in many countries. As well as cocaine, 
methamphetamine (METH) has become one of the most widely used psychostimulants in the world 
(World drug report 2017, United Nations Office on Drugs and Crime). According to the report from 
the Health, Labour and Welfare Ministry of Japan (http://www.mhlw.go.jp/bunya/iyakuhin/ 
yakubuturanyou/dl/pamphlet_04.pdf), the population suffering METH abuse in Japan keeps a higher 
level than the other drug abusers, and recently the recidivism rate of METH abuse also increases 
gradually. Similar to Japan, China has one of the highest rates of METH abuse in the world. By now, 
over 14 million of Chinese have tried the drug (http://gb.cri.cn/42071/2015/06/24/107s 
5007120.htm). Moreover, in the United State of America, it is reported that nearly half a million 
people have used METH every week (Lee and Rawson, 2008). 
METH is a derivative of amphetamine, with a stronger ability to induce psychological dependence. 
A lot of harmful effects from METH abuse have been identified, including addictive syndromes, 
psychiatric disorders, and neurological complications (Grant et al. 2012). Despite the widespread of 
METH abuse and its associated problems, no therapeutic approaches have been demonstrated to be 
effective. The most common treatment for METH-induced dependence is detoxification, which is 
usually accompanied by serious withdrawal symptoms. Antipsychotic medicines, antidepressant and 
antianxiety medicines were applied to ameliorate this discomfort during the withdrawal. However, 
METH-induced pharmacological changes in the brain are still retained, with an all life suffering and 
high possibilities to relapse even after the therapy (Karila et al., 2010). Therefore, in spite of much 
effort, the mechanism of the establishment in METH-induced dependence remains to be clarified, 
and novel therapeutic medicines are still needed to be developed. 
Accumulating evidences indicate a strong link between METH-induced dependence and the 
function of rewarding circuit in the brain (Koob, 1992). The mesolimbic dopaminergic projection 
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from the ventral tegmental area (VTA) to the nueleus accumbens (NAc) is the most central part of 
the rewarding system (Groenewegen et al., 1999). It releases dopamine (DA) in the NAc in response 
to rewarding stimuli. Alternatively, the GABAergic projection from the NAc to the VTA and the 
γ-aminobutyric acid (GABA) interneurons in the NAc also play an important role in the modulation 
of reward-driven behaviors (Tepper and Bolam, 2004; Russo and Nestler, 2013). Therefore, it is 
indicated that the NAc is a key brain region in the rewarding circuit, and the investigations of the 
NAc could offer some ways to elucidate the cause of METH-induced dependence, as well as to 
contribute to the development of therapeutic strategy. 
Main pharmacological action of METH is the introduction of dopamine release at the synapse 
terminal by reversing the function of DA transporter (Karila et al., 2010). The projected 
dopaminergic synapse in the NAc is an original target for METH. Significant elevation of 
extracellular DA levels in the NAc has been reported after METH administration (Volkow et al. 
2011; Marshall and O'Dell 2012). It is suggested that the dopaminergic dysfunction in the NAc is 
associated with METH-induced dependence.  
Accumbal GABA neurons interact with mesolimbic DA projections and regulate the DA release in 
the NAc (Tepper and Bolam, 2004). For example, infusion of the GABAA receptor antagonist 
bicuculline into the NAc increases accumbal DA release in rats (Yan 1999; Rahman and McBride 
2002). Consistent with that, infusion of the GABAA receptor agonist muscimol into the NAc inhibits 
accumbal DA release in rats (Ferraro et al. 1996). It is suggested that the regulation of the accumbal 
local neurons (approximately 99% are GABA neurons in the NAc; Russo and Nestler, 2013) controls 
the dopaminergic release in the NAc, which is linked with the pathological mechanism of 
METH-induced dependence. 
In addition to the functions of the dopaminergic and GABAergic neuronal systems in the NAc, 
METH-induced adaptive molecular changes in the brain also suggest that the alterations in gene 
regulation contribute to the addictive phenotype in humans and animals. A variety of molecules are 
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associated with the genetic and behavioral changes on METH-induced dependence, such as cAMP 
response element-binding protein (CREB) (Barrot et al., 2002), brain-derived neurotrophic factor 
(BDNF) (Berton et al., 2006; de la Tremblaye et al., 2016), tumor necrosis factor-α (Nakajima et al., 
2004), ΔFosB (Zachariou et al., 2006), nuclear factor-κB (Ang et al., 2001), orexin (Azogu and 
Plamondon, 2017) and Shati/Nat8l (Niwa et al., 2007a; Miyamoto et al., 2014; Toriumi et al., 2015). 
However, key signaling pathways and novel molecular cascades relevant to METH-induced adaptive 
phenomena remain to be investigated. 
Furthermore, in order to find some novel and effective therapeutic methods for drug dependence, 
several studies focused on the traditional medicine. Although the application of herbal medicine has 
a long history, clinical studies for drug dependence and addiction (such as opiate, cocaine, and 
nicotine) by using traditional medicine is still in an initial stage, and only in the last 20 years some 
compounds isolated from herbal medicine have been proved a possibility for the therapy of drug 
dependence (Lu et al., 2009). In the theory of traditional medicine, the effects of psychostimulants 
are considered as pathogenic heat. On the other hand, several herbal medicines, such as American 
ginseng, Withania Somnifera and Radix Puerariae, have been indicated as a promising method to 
deal with psychostimulant addiction; because of their pharmacological effects in traditional medicine 
are invigoration and cold in property, which is against the pathogenic heat induced by 
psychostimulants. Thus, the investigation on the active constituents in these herbal medicines might 
open a breach to find some novel compounds for the treatment of METH addictive symptoms. 
The present study concentrated on the adaptive molecules and traditional medicines for the 
therapy that are relevant to pharmacological effects of METH. The function of the NAc, including 
dopaminergic and GABAergic neuronal activities were investigated to elucidate the inhibitory 
mechanism in the METH-induced dependence. 
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CHAPTER 1 
Inhibitory role of accumbal TMEM168-regulated osteopontin system in METH-induced 
dependence in mice 
 
Introduction 
Repeated METH exposure induces psychiatric disorders which are associated with adaptive 
changes in the brain at the genetic and molecular levels (Darke et al., 2008; Grant et al., 2012). The 
mechanisms of these adaptive changes are complex, suggesting that the long-lasting influences on 
the gene and protein expression usually occur within specific brain subregions, including the NAc, 
striatum, prefrontal cortex and hippocampus, and then regulate the behavioral alterations induced by 
METH (Godino et al., 2015; Niwa et al., 2007a; Grant et al., 2012; Miyamoto et al., 2014). 
As mentioned in the previous reports, the NAc is a central part of the rewarding circuit, which is 
sensitive to the METH-induced adaptive changes in the brain (Nestler, 2012; Russo and Nestler, 
2013). Thus, focusing on the NAc, accumbal mRNA expression changes in mice after repeated 
METH (2 mg/kg) exposure for 6 days were analyzed. Some response molecules were found by 
polymerase chain reaction-select cDNA subtraction (Niwa et al., 2007a; Fig. 1). The molecules, of 
which the mRNA increased with more than 20 folds in the NAc of the METH-treated mice compared 
to control, were including transmembrane protein 168 (TMEM168) (GenBank accession number 
NM_028990). TMEM168 comprises 697 amino acid residues, including some putative 
transmembrane domains (Fig. 2). The tmem168 gene expresses in both humans and in mice 
(Mammalian Gene Collection Program Team, 2002). However, the studies of TMEM168 remain in 
an initial stage, and the neuronal function of TMEM168 was still unknown. The tmem168 is a 
primary gene target of transcription factor AP-2 gamma in breast carcinoma cells, but its detail 
function is unknown (Woodfield et al, 2010). The tmem168 is identified as a candidate gene with 
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long-range epigenetic silencing regions in prostate cancer cells. However, the present analysis 
indicates no epigenetic differences between the normal group and the cancer group of cells (Coolen 
et al., 2010). TMEM168 mRNA is a candidate target of age-related miRNA miR-125b in human 
dermal fibroblasts, although the protein level of TMEM168 does not alter with age (Waldera-Lupa et 
al., 2014). By the established yeast two-hybrid screening, phosphotyrosine-dependent protein-protein 
interactions are observed between TMEM168 and Crk-like protein, but the direct epitopes that 
mediate these interactions remains unknown (Grossmann et al., 2015). Similarly, by the yeast 
two-hybrid screening, TMEM168 has been identified as a molecule interacting with the extracellular 
matrix protein osteopontin (OPN) (Long et al., 2012). However, the detail relationship between 
TMEM168 and OPN is unclear. 
The present study investigated the physiological role of TMEM168 in the NAc in vivo and then 
tried to elucidate the effect of accumbal TMEM168 overexpression on METH-induced psychotic 
behaviors in mice. The adeno-associated virus (AAV) vectors comprising tmem168 cDNA were 
microinjected into the NAc of mice, so that the accumbal TMEM168 mRNA was increased 
significantly (NAc-TMEM mice) compared to the control mice (NAc-Mock mice). A battery of 
behavioral paradigms without METH treatment was performed by using the NAc-TMEM and 
NAc-Mock mice，and TMEM168 was associated with anxiety and abnormal sensorimotor gating in 
mice. Moreover, the inhibitory effects of the increased TMEM168 expression were observed on 
METH-induced hyperlocomotion, conditioned place preference (CPP) and accumbal extracellular 
DA elevation. In order to characterize the inhibitory mechanism of TMEM168 overexpression on 
METH-induced dependence furtherly, OPN was identified as an interacting molecule for TMEM168 
to affect the rewarding circuit in the NAc.  
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Figure 1 A simplified schema of TMEM168 searching by PCR-select cDNA subtraction 
 
 
 
 
Figure 2 The amino acid sequence of TMEM168 (Yellow character: Putative transmembrane 
region) 
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Materials and Methods 
 
Animals  
Male C57BL/6J mice (Nihon SLC, Inc. Hamamatsu, Japan) (8-week-old; 22–27 g) were housed in a 
room with a 12 h light/dark cycle (8 am–8 pm). All procedures followed the National Institute of 
Health Guideline for the Care and Use of Laboratory Animals and were approved by the Animal 
Experiments Committee of the University of Toyama (Permit Number A2015pha-21). 
 
Drugs 
METH (Dainippon Sumitomo Pharmaceutical Co. Ltd., Osaka, Japan) was dissolved in saline (0.1 
mg/mL). Human osteopontin standard (OPN; R&D System, MN55413) was dissolved in saline at the 
concentration of 0.12 μg/μL. Diazepam (DZP; 045-18901; Wako Pure Chemical Industries, Japan) 
was dissolved in saline and 1% Tween80 at the concentration of 30 μg/mL. Risperidone (RIS; 
R3030; Sigma-Aldrich, Japan) was dissolved in saline at the concentration of 1 μg/mL. All other 
reagents were obtained from standard commercial sources.  
 
Adeno-associated virus (AAV) vector Production  
The production of AAV vector was performed according to previously described methods 
(Krzyzosiak et al, 2010; Muramatsu et al., 2010). The AAV vector plasmids consist of an expression 
cassette, including a human cytomegalovirus (CMV) immediate-early promoter, followed by 
TMEM168 (TMEM168: GenBank accession number NM_028990) cDNA, and a simian virus 40 
polyadenylation (SV40 poly A) signal sequence, between the AAV3 genome with inverted terminal 
repeats. Subsequently, the vector plasmid, an adenoviral helper plasmid, and an AAV1 vp/AAV2 rep 
expression plasmid were transfected into HEK293 cells, so that the recombinant AAV vectors were 
produced. The purity of the recombinant viruses was confirmed by quantitative real time reverse 
transcription polymerase chain reaction (RT-PCR). 
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Microinjection of AAV vector 
Mice were anesthetized with a combination anesthetic (medetomidine [0.3 mg/kg], midazolam [4.0 
mg/kg], and butorphanol [5.0 mg/kg]), and were fixed in a stereotactic frame (SR-5M, Narishige, 
Tokyo, Japan). The injection site in the NAc (1.5 mm anterior from bregma, 0.8 mm lateral, and 3.9 
mm below the skull surface) was determined by a published atlas (Paxions and Franklin, 2008). 
AAV-TMEM168, or a mock vector suspension (0.7 μl/side) was injected into the NAc of mice 
bilaterally (NAc-TMEM mice or NAc-Mock mice) in a total volume of 0.7 μL/side at a rate of 0.05 
μL/min by the syringe with a steel needle (Hamilton, 701N, 10μl, Nevada, USA). Following the end 
of the injection, the needle was left in the brain for 10 min to allow for diffusion. The AAV vector 
injected mice were used for experiments over 3 weeks later.  
All procedures followed the Guideline for Recombinant DNA Experiment from the Ministry of 
education culture, sports, science and technology, Japan and were approved by the Gene 
Recombination Experiment Safety Committee of the University of Toyama (Permit Number 
G2015pha-21). 
 
Quantitative real time RT-PCR analysis 
In the case of tissue mRNA detection, total RNA extraction from the mice tissues was carried out 
using the RNeasy Plus Mini Kit protocol (Qiagen, Tokyo, Japan). RNA (500 ng) from each tissue 
sample was transcribed into the cDNA using the Prime Script RT reagent kit (Takara, Kusatsu, 
Japan). Quantitative real time RT-PCR was run in a Thermal Cycler Dice Real Time System (Takara) 
using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster, CA), with cDNA and gene 
specific primers (1 μM) following the manufacturer’s instructions. 36B4 transcript was used as the 
internal control. The primers of mouse TMEM168 used for real time RT-PCR were as follows: 
5'-GACAGAATCATGGCATCCAAAGG-3', and 5'-ATGGACTCCAGCGGCAAGACAA-3'.  The 
36B4 transcript amount was quantified using primers 5'-ACCCTGAAGTGCTCGACATC-3', and 
5'-AGGAAGGCCTTGACCTTTTC-3'. 
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In the case of mRNA detection from primary cultures, the preparation of cultured rat primary neuron, 
cultured astrocyte and cultured microglia were described as previous methods (Fukuchi et al., 2015; 
Ogura et al., 2006; Morioka et al., 2014). Total RNA (500 ng) from each cells sample was 
transcribed into the cDNA and then the quantitative real time RT-PCR was run following the 
manufacturer’s instructions. β-actin transcript was used as the internal control. The primers of rat 
TMEM168 used for real time RT-PCR were as follows: 5'-CAGCCCACAAATGGAATCTT-3', and 
5'-GCATTGAGCATGCCAGTAGA-3'. The β-actin transcript amount was quantified using primers 
5'-TTCAACACCCCAGCCATGTA-3', and 5'-GTGGTGGTGAAGCTGTAGCC-3'. 
 
In situ hybridization 
The mice were anesthetized with sodium pentobarbital (50mg/kg i.p.) and perfused through the left 
ventricle, first with 50 ml of phosphate-buffered saline (PBS) to flush the blood vessels quickly, 
followed by 50 ml of cold PBS containing 4% paraformaldehyde (PFA). The brains were removed 
from the skull, postfixed in 4% PFA at 4°C overnight, followed by cryoprotection in 30% sucrose in 
PBS overnight at 4°C. The brain sections (20μm) were treated with digoxigenin (DIG) labeled 
TMEM168 antisense riboprobes (accession no. NM. 028990.4; nucleotides 1697-2296). After 
hybridization, the sections were incubated with anti-DIG-AP Fab fragments. After washing, sections 
were treated with nitro blue tetrazolium chloride / 5-bromo-4-chloro-3-indolyl-phosphate. After 
washing at room temperature for 5 min, the development was stopped by incubation in 1 × TE (10 
mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.00). The histochemical staining signal was observed by an 
AxioObserver Z1 (Carl Zeiss, Jena, Germany). 
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Schedule of the behavioral tests 
The behavioral tests without drug administration were performed in the following order: locomotor 
activity test, Y-maze test, novel object recognition test, social interaction test, light/dark box test, 
elevated plus maze test, prepulse inhibition test, tail suspension test and forced swim test.  
In the other animal test with drug administration or infusion, each test was performed with different 
group of mice. 
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Locomotor activity test 
Mice were placed into a Plexiglas box with a frosting Plexiglas floor (40 × 40 × 30 cm), and the test 
was performed for 60 min using digital counters with infrared sensors (Scanet MV-40; MELQEST, 
Toyama, Japan). Mice were administered with METH (1 mg/kg s.c.) or saline and locomotor activity 
was measured immediately after the administration.  
In the case of locomotor activity tests using OPN, the 
procedure was done with some modifications. Mice were 
infused with OPN (0.03 μg/side) or PBS for 1 min. After 
10 min for recovery in the home cage, the mice were 
treated with METH (1 mg/kg, s.c.) or sline, and 
locomotor activity was measured immediately for 60 min. 
 
Y-maze test 
Y-maze test was performed, according to a previously described method (Furukawa-Hibi et al., 2012). 
The three-arm maze (each arm measuring 40 cm × 3 cm × 12 cm) was used for the test. Mice were 
placed at the end of one arm and were allowed to move 
freely through the maze for 10 min. During this time, 
the arm entries were enumerated. Alternation was 
defined as successive entries into the three arms on the 
overlapping triplet sets. The percentage alternation was 
calculated using the following formula: (number of 
alternations)/(total number of arm entries-2) × 100. 
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Novel object recognition test 
Novel object recognition test was performed, according to a previously described method 
(Furukawa-Hibi et al., 2012). After habituation for 3 days, the NAc-Mock or NAc-TMEM mice were 
allowed to explore two familiar floor-fixed objects (A and B) in a Plexiglas box (30 cm × 30 cm × 35 
cm) for 10 min (familiar process). The familiar object A and a novel object C were set in the 
Plexiglas box 24 h after the trail and the mice were 
allowed to explore the novel object process for 10 min 
(novel process). The exploratory preference percentage 
was calculated using the following formula: (approach 
time of object B or C)/(total approach time of the two 
objects in each process) × 100. 
 
Social interaction test 
Social interaction test was performed according to a previously described method (Furukawa-Hibi et 
al., 2010). The apparatus for this test was designed as a Plexiglas box (60 cm × 40 cm × 22 cm) 
comprising three connected chambers. After habituation 
for 2 days, both the NAc-Mock and NAc-TMEM mice 
were randomly assigned to a partner male mouse, which 
was confined to one side of the chamber. The test mice 
were placed in the apparatus for 10 min and the total 
duration they spent interacting with the partner mouse 
was recorded. 
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Elevated plus-maze test 
Elevated plus-maze test was performed according to a previously described method (Alkam et al., 
2007). The apparatus comprised four black plastic arms (25 cm × 5 cm). Two opposite arms were 
enclosed by walls (15 cm in height) and the other two “open” arms had only a small rim (0.2 cm) 
around the edges. The apparatus was elevated to a 
height of 70 cm above the floor level. For testing, mice 
were placed in the center region facing an open arm, and 
were allowed to freely explore the maze for 10 min. The 
time spent on open arms and the number of entries into 
the open arms was evaluated. 
 
Light–dark box test 
Light–dark test was performed according to a 
previously described method (Alkam et al., 2007). The 
apparatus comprised two plastic chambers. The dark 
chamber (black plastic) measured 15 cm × 15 cm × 20 
cm (l × w × h) and was covered by a lid. The light 
chamber, 15 cm × 15 cm × 20 cm (l × w × h), made of 
transparent plastic, was brightly illuminated from 
above with tubular fluorescent lamps (1000 lux). Mice were placed into the dark chamber and their 
behaviors were monitored by Scanet MV-40 LD (MELQUEST) for 10 min. The time spent in the 
light box was measured.  
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Tail suspension test 
Tail suspension test was performed according to a previously 
described method (Furukawa-Hibi et al., 2010). The mice were 
suspended by their tails, i.e., the body dangled in the air, with the 
head pointing downward for 10 min. The duration of immobility 
from 2 min to 6 min within the test was recorded visually. 
 
Forced swimming test 
Forced swim test was performed according to a previously 
described method (Furukawa-Hibi et al., 2010). Mice were placed 
in a transparent Plexiglas cylinder (diameter: 14.5 cm; height: 19 
cm), ﬁlled with water (depth: 15 cm; temperature: 25 °C) for 10 
min. The immobility time was monitored by Scanet MV-40 AQ 
(MELQUEST) from 2 min to 6 min within the test. 
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Auditory prepulse inhibition test 
Prepulse inhibition (PPI) test was performed according to a previously described method (Arai et al., 
2008). The test was evaluated using the SR-LAB apparatus (San Diego Instruments, CA, USA). 
Briefly, the test was performed by exposing the animals to a 70 dB background noise. After a 5 min 
acclimatization period, 5 pulses (120 dB each lasting 40 ms) were presented. Subsequently, the 
randomly prepulse plus pulse trials were administered as a 20 ms prepulse of 74, 78, 82 or 86 dB, 
followed by a 100 ms delay and a startle pulse (120 dB each lasting 40 ms). Eventually, 5 pulses 
(120 dB each lasting 40 ms) were presented once again. The PPI was calculated as (1 − [startle 
amplitude on prepulse + pulse trial/mean startle amplitude on pulse alone trials]) × 100. 
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Conditioned Place Preference (CPP) test 
The CPP tests were performed according to a previously described method (Miyamoto et al., 2014). 
Briefly, the apparatus consisted of two Plexiglass boxes (both 15 × 15 × 15 cm): one is black and the 
other is transparent, which are separated by a sliding door (10 × 15 cm high). The CPP procedure 
was performed as shown in Figure 3. Preconditioning was performed for 15 min once a day on days 
1–3, and time spent in each compartment was measured on day 3 using the LD mode of a Scanet 
MV-40 (MELQEST) instrument. Conditioning was performed on days 4–9, and on days 4, 6, and 8, 
mice were treated with METH (1 mg/kg, s.c.), and were confined to either the transparent or black 
compartment for 20 min. On days 5, 7, and 9, mice were administered saline and were placed in the 
compartment that was not used for METH-conditioning, for 20 min. Post-conditioning was 
performed on day 10. In this procedure untreated mice were allowed to move freely between 
compartments, and the time mouse spent in each compartment was measured for 15 min. In the case 
of CPP tests using OPN, the schedule of procedure was similar (Fig. 4) with some modifications in 
the conditioning process. On days 4, 6, and 8, mice were infused with OPN (0.03 μg/side) for 1 min. 
After 10 min for recovery in the home cage, the mice were treated with METH (1 mg/kg, s.c.), and 
were confined to either the transparent or black compartment. On days 5, 7, and 9, mice were infused 
with OPN (0.03 μg/side) for 1 min. After 10 min for recovery in the home cage, the mice were 
treated with saline, and were placed in the compartment that was not used for METH-conditioning. 
The CPP behaviors were expressed as Post–Pre values, which were calculated as [(post value) − (pre 
value)] to reflect the difference in time spent in METH and saline-conditioning sides in the post and 
pre-conditioning stages, respectively. 
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Figure 3 Protocol for CPP analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Protocol for CPP analyses using OPN.  
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Intra-accumbens injection procedures 
Intra-accumbens injection was performed according to previously described methods (Wiggins et al., 
2011; He et al., 2015), with minor modifications. Mice were anesthetized with pentobarbital (50 
mg/kg, i.p.) and stereotaxically implanted with bilateral guide cannula aimed at the NAc (+1.5 mm 
anterolateral, ±0.8 mm mediolateral from bregma, and +3.9 mm dorsoventral to dura). The guide 
cannula was secured into the skull with a stainless steel screw and dental acrylic cement. After 48 
hours, mice were then gently hand-held for the injection procedure. Mice were microinjected with 
OPN (0.03 μg) or PBS (vehicle) in a total volume of 0.25 μL/side at a rate of 0.25 μL/min using a 
microdrive pump (ESP-64; EICOM, Kyoto, Japan), and injectors were left in the NAc for an 
additional 30 sec to allow for diffusion after the 1 min infusion period. 
 
Tissue extraction for high-performance liquid chromatography (HPLC) 
From each brain, the NAc tissue was bilaterally extracted and homogenized in a homogenizing 
buffer, containing 200 mM perchloric acid and 100 μM ethylenediaminetetraacetic acid (EDTA). The 
homogenates were kept in ice for 30 min and were then centrifuged at 20,000 × g for 15 min at 0 °C. 
Supernatant was collected and was adjusted to pH 3.0 by adding 1 M sodium acetate. After filtration 
(0.45 μm Membrane Filter, MF-Millipore, Japan), the extraction samples was preserved at −80 °C 
until the measurement by HPLC. 
 
In vivo microdialysis 
In vivo microdialysis was performed according to a previously described method (Miyamoto et al., 
2014). The guide cannula (AG-4, Eicom, Kyoto, Japan) was implanted into the NAc (+1.5 mm 
anterolateral, +0.7 mm mediolateral from bregma, and +3.25 mm dorsoventral from dura mater). On 
the following day, a dialysis probe (A-I-4-01, Eicom) was inserted into the guide cannula, and a 
ringer’s solution (147 mM NaCl, 4 mM KCl, and 2.3 mM CaCl2) was continuously perfused through 
the probe into the left side of the NAc. 
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In the case of GABA dialysis, the dialysate was collected every 30 min at a rate of 1.0 μL/min by a 
fraction collector (EF-80; Eicom), placed in biotubes and preserved at −80 °C until it was subjected 
to HPLC. High K⁺-stimulation (100 mM) was applied for 15 min, 4.5 h after the probe insertion. The 
baseline of extracellular GABA levels was the mean of the averages amount of the last three samples 
before high K⁺-stimulation. The 100 mM K+ solution means an identical amount of sodium is 
replaced in the ringer’s solution with potassium. 
In case of dopamine dialysis, the dialysate was 
collected in 15 min fractions at a rate of 0.5 
μL/min and was simultaneously subjected to 
HPLC. Four hours after the probe was inserted, 
the baseline of DA and serotonin levels was 
measured, which was the mean of the last three 
samples before METH administration (1 mg/kg) 
or high K⁺-stimulation (100 mM). 
 
HPLC detection for neurotransmitters 
Using sampling injector (M-500; Eicom), 7 μL of o-phthalaldehyde solution (4 mmol/L) and 0.04% 
mercaptoethanol in carbonate buffer (pH 9.5) were added to a 21 μL of dialysate sample or extraction 
sample. Subsequently, 21 μL of the mixture was injected into the HPLC system (HTEC-50; Eicom). 
GABA was separated on the SA-50DS column (Eicom), which was maintained at 25 °C, using a 
phosphate buffer (pH 3.5) containing EDTA (0.5 μg/L) and 50% methanol as the mobile phase with a 
flow rate of 500 μL/min. An electrochemical detector that used a glassy carbon and a working 
electrode (set at +600 mV) against a silver–silver chloride reference electrode (WE-GC; Eicom) was 
used to quantify the compounds. Chromatograms were controlled by an integrator (PowerChrom: 
AD Instruments, NSW, Australia) connected to a personal computer. 
In the case of dopamine detection, the dialysate was injected into the HPLC system (HTEC-50; 
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Eicom) directly by an auto injector (Eicom). Dopamine and serotonin were separated on a PP-ODS 
column (Eicom), which was maintained at 25 °C, using a phosphate buffer (pH 6.0) containing 
decane sulfonic acid (0.5 g/L), EDTA (50 μg/L), and 1% methanol as the mobile phase at a flow rate 
of 500 μL/min. An electrochemical detector that used a glassy carbon working electrode (set at + 400 
mV) against a silver–silver chloride reference electrode (WE-3G; Eicom) was used to quantify the 
compounds. Chromatograms were controlled by an integrator (PowerChrom: AD Instruments, NSW, 
Australia) connected to a personal computer. 
 
Cell culture and plasmid transfection 
The experimental procedure was conducted as described previously (Cen et al., 2008). COS-7 cells 
were transfected with either the CMV-flag-Mock vector, or the CMV-flag-TMEM168 vector, using 
Lipofectamine 2000 (Invitrogen) for 24 h. 
 
Western blotting 
COS-7 cells or NAc tissues homogenates (10 μg total proteins) were separated using sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (10% poly-acrylamide) and blotted onto a polyvinylidene 
difluoride membrane. The membranes were incubated with primary antibodies against OPN (1:5000; 
mouse, DSHB, USA), Syntaxin 6 (1:1000; mouse, Cell Singaling, USA), TMEM168 (1:1000; rabbit, 
Abcam, Japan), and GAPDH (1:5000; mouse, MBL, Japan) antibodies, overnight at 4°C. Following 
this, membranes were probed with anti-mouse or anti-rabbit immunoglobulin G (IgG), HRP-linked 
antibody (1:5000; GE Healthcore, UK) for 1 h at room temperature. Fluorescence of the protein band 
was detected by using ImageQuant LAS4000mini (GE Healthcore). The immunoreactivity of 
western blots was quantified by densitometry, using ImageJ software, and normalized to GAPDH. 
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Immunostaining 
For the immunostaining analysis, the transfected COS-7 cells were fixed with 4% PFA for 15 min 
and permeabilized with 0.25% Triton X-100 for 15 min, followed by blocking in 10% goat serum for 
1 h. The cells were incubated overnight with a primary antibody Syntaxin 6 (1: 50; mouse, Cell 
Signaling), and anti-flag (1:200; rabbit Sigma, Japan), at 4°C. The cells were subsequently incubated 
with CF488A anti-mouse goat IgG (1: 1000, Nacalai tesque) or Alexa Fluoro 594 anti-rabbit goat 
IgG (1: 1000, Nacalai tesque) for 2 h at room temperature. The sections were observed by using 
AxioObserver Z1 (Carl Zeiss). 
 
 
Isolation of Golgi fraction 
Golgi in the NAc of mice was isolated by Percoll density gradient centrifugation, according to 
previously described methods (Hara-Kuge et al., 2004; Shinohara et al., 2008). Briefly, the NAc 
tissues of four mice were minced by eight strokes in a glass homogenizer in ice-cold homogenizing 
buffer composed of 250 mM sucrose, 20 mM HEPES (pH 7.2), 1 mM ethylene glycol  
bis(2-aminoethyl ether)-tetra acetic acid, 0.1 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride and 
dispersed by eight strokes in a glass homogenizer. Homogenates were centrifuged at 150×g for 5 min 
(P1: the pellet), and supernatant was centrifuged at 1,500×g for 10 min. The pellet was suspended in 
homogenizing buffer containing 40% Percoll (GE Healthcore), and centrifuged at 20,000×g for 20 
min to obtain seven fractions from the top side to the bottom side, which were labeled by numbers 
from 7 to 1. The seven fractions were detected by western blotting, using the 15 μL volume. 
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Immunoprecipitation and ELISA analyses 
Co-immunoprecipitations of TMEM168-flag and OPN were carried out from total cell lysates in 300 
μL volume, which was centrifuged at 12,000×g for 10 min. Supernatant was incubated with 3 μL 
anti-flag antibody (Sigma-Aldrich Sigma) overnight at 4°C, then 60 μL of Protein G Sepharose Fast 
Flow (GE healthcare) were added, and incubation continued for another 3 hours. The pellet was 
washed 3 times and diluted in the sample buffer (62.5 mM Tris-HCl pH 6.8, 25% glycerol, 2% SDS, 
0.01% bromophenol blue, 350 mM dithiothreitol). The samples were analyzed by western blotting 
with anti-OPN (1:5000; DSHB) antibody. 
To detect extracellular OPN, matrix metalloproteinase inhibitor batimastat (50 μl; Millipore, Billerica, 
MA) was added to the cell medium after vector transfection. Then the contents of OPN in the cell 
medium were analyzed using the Osteopontin Quantikine ELISA Kit (R&D Systems Inc., 
Minneapolis, MN), following the manufacturer’s instructions. 
 
Statistical Analyses 
All data were expressed as mean ± standard error of the mean (S.E.M.). Statistical differences 
between the two groups were determined using a Student’s t test. Statistical differences among 
values for individual groups were determined by one-way analysis of variance (ANOVA), followed 
by the Bonferroni’s post hoc tests when F ratios were significant (p < 0.05). Statistical differences 
between the two groups after different drug administration were determined by two-way ANOVA, 
followed by the Bonferroni’s post hoc tests when F ratios were significant (p < 0.05). To analyze the 
development of in vivo microdialysis, statistical differences were determined by two-way ANOVA 
with repeated measurement, followed by the Bonferroni’s post hoc tests (Prism version 5). 
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Results 
 
Expression pattern of TMEM168 mRNA 
The expression of TMEM168 mRNA was discovered in the individual organs (brain, heart, lung, 
stomach, liver, kidney, spleen, small intestine, testis, ovary, and uterus) of mice. The TMEM168 
mRNA was expressed highly in the brain compared to other organs (Fig. 5A). In situ hybridization 
analysis of sagittal brain sections indicated that TMEM168 mRNA expressed widely in the whole 
brain (Fig. 5B). Expression of TMEM168 mRNA was analyzed in the primary culture of neurons, 
astrocytes, and microglia, and was observed highly in neurons compared to astrocytes and microglia. 
(Fig. 5C) 
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Figure 5 Systemic and cerebral distribution of TMEM168 mRNA (A) TMEM168 mRNA highly 
expressed in mice brain, compared to other organs. Values are mean ± S.E.M.; n=3. (B) Sagittal 
section of the whole brain in mice was analyzed by in situ hybridization using TMEM168 sense 
(upper panel), and anti-sense probes (below panel). Same results were obtained by repeating the 
experiments 3 times, using 3 different mice. (C) TMEM168 mRNA expressed highly in primary 
cultured neurons, compared to primary cultured astrocytes and microglia. Values are mean ± S.E.M.; 
n=3. 
 
 
 
 
A 
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Overexpression of TMEM168 mRNA in the NAc after METH administration and AAV vector 
microinjection 
After repeated administration with METH (2 mg/kg/day, s.c.) or saline for 6 days, TMEM168 
mRNA significantly increased in the NAc and hippocampus, compared to the saline administration 
group. The expression of accumbal TMEM168 mRNA revealed about 2.0 ± 1.0 folds compared to 
saline control (p < 0.05) (Fig. 6A).  
To make accumbal TMEM168 overexpression model, the AAV TMEM168 vector was injected in 
the NAc. The results of the in situ hybridization analysis showed that TMEM168 mRNA was 
obviously overexpressed in the injection site within the NAc (Fig. 6B). Accumbal TMEM168 mRNA 
levels in the NAc-TMEM mice increased 7.4 ± 0.18 folds, compared to that in NAc-Mock mice (p < 
0.01) (Fig. 6C). 
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Figure 6 The relationship between TMEM168 and the pharmacological actions of METH in the 
naïve mice, and the AAV vector injected mice (A) Expression of TMEM168 mRNA was analyzed in 
various brain regions of mice after repeated saline and METH (2 mg/kg, s.c. for 6 days) 
administration. Values are mean ± S.E.M.; n=5; *p < 0.05 vs. saline group (Student-t test). PFC: 
prefrontal cortex, HIP: hippocampus, STR: striatum, NAc: nucleus accumbens, TH: thalamus, CB: 
cerebellum. (B) The site of microinjection in NAc-TMEM mice and NAc-Mock mice was confirmed 
by in situ hybridization for TMEM168 mRNA. Upper panel and below panel indicate the results 
from NAc-TMEM mice and NAc-Mock mice, respectively. (C) TMEM168 mRNA levels in the 
NAc-Mock mice and NAc-TMEM mice have been presented as relative to the expression of 36B4. 
Values are mean ± S.E.M.; n=10; **p < 0.01 vs. NAc-Mock (Student-t test). 
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Overexpression of TMEM168 in the NAc of mice did not influence the locomotion, spontaneous 
alternation, cognitive ability, social interaction, and depression-like behaviors 
A series of behavioral procedures were performed to investigate the changes in the emotional 
behaviors induced by TMEM168 overexpression in the NAc. The NAc-TMEM mice showed no 
changes in locomotion in a novel environment during locomotor activity test (Fig. 7A), spontaneous 
alternation during Y-maze test (Fig. 7B), exploratory preference percent during novel object 
recognition test (Fig. 7C), approach time to another mouse during three-chamber social interaction 
test (Fig. 7D), and immobility time during tail suspension test (Fig. 7E) and forced swimming test 
(Fig. 7F) when compared to the NAc-Mock mice. 
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Figure 7 Similar preferences in locomotor activity, Y-maze, novel object recognition, three chambers, 
tail suspension, and forced swimming tasks in the NAc-TMEM mice compared with the NAc-Mock 
mice (A) The locomotor activity in the NAc-Mock and NAc-TMEM mice were measured for 60 min 
(No significant difference; Student-t test). (B) Working memory was assessed in the Y-maze 
spontaneous alternation task in the NAc-Mock and NAc-TMEM mice (No significant difference; 
Student-t test). (C) Cognitive function was assessed in the novel object recognition task. Percentage 
of total exploratory time on the novel object was expressed as exploratory preference (%) (No 
significant difference; one-way ANOVA followed by the Bonferroni’s post hoc tests). (D) Social 
interaction was assessed in the three chambers task. Average time (10 min per phase) spent in the 
chamber with an object or a stranger mouse was detected (No significant difference; one-way 
ANOVA followed by the Bonferroni’s post hoc tests). (E) Immobility time of the NAc–-Mock and 
NAc-TMEM mice in the tail-suspension task was measured for 5 min (No significant difference; 
Student-t test). (F) Immobility time of the NAc-Mock and NAc-TMEM mice in the forced 
swimming task was measured for 5 min (No significant difference; Student-t test). Values are 
presented as mean ± S.E.M. N = 9. 
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Overexpression of TMEM168 in the NAc induced the increased anxiety and decreased 
sensorimotor gating in mice 
The NAc-TMEM mice indicated the decreased counts (Fig. 8A) (p < 0.05) and time (Fig. 8B) (p < 
0.05) into the open arms in the elevated plus-maze test. In the light/dark box tasks, time in the light 
box was decreased in the NAc-TMEM mice (Fig. 8C) (p < 0.05). It is suggested that overexpression 
of TMEM168 in the NAc increased anxiety in mice. Although the startle responses were not affected 
(Fig. 8D), decreased sensorimotor gating in the NAc-TMEM mice was observed in the auditory PPI 
test (Fig. 8E) (p < 0.05). It is suggested that overexpression of TMEM168 in the NAc induced 
sensorimotor gating deficit in mice. 
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Figure 8 Increased anxiety and decreased PPI in the NAc-TMEM mice compared with the 
NAc-Mock mice (A) Number of entries spent on open arms were measured for 10 min in the 
elevated plus-maze task; N = 9; Values are presented as mean ± S.E.M. *p < 0.05 vs. NAc-Mock 
(Student-t test). (B) Time spent on open arms was measured for 10 min in the elevated plus-maze 
task; N = 9; Values are presented as mean ± S.E.M. *p < 0.05 vs. NAc-Mock (Student-t test). (C) 
Time in the light box was measured for 10 min in the light/dark box task; N = 9; Values are presented 
as mean ± S.E.M. *p < 0.05 vs. NAc-Mock (Student-t test). (D) Startle responses were measured at 
70, 80, 90, 100, 110, and 120 dB, respectively (background noise: 70 dB). N = 9; Values are 
presented as mean ± S.E.M. No significant difference between NAc-TMEM and NAc-Mock mice 
(one-way ANOVA followed by the Bonferroni’s post hoc tests). (E) PPI was measured for 74, 78, 82, 
and 86 dB, respectively, of the prepulse intensity (background noise: 70 dB). Values are presented as 
mean ± S.E.M. N = 9. *p < 0.05 vs NAc-Mock (one-way ANOVA followed by the Bonferroni’s post 
hoc tests). 
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Increased anxiety induced by TMEM168 overexpression in the NAc were reversed by the 
administration of diazepam 
Diazepam is a FDA (Food and Drug Administration in USA)-approved benzodiazepine known to 
alleviate anxiety, by activating the ionotropic GABAA receptors (Riss et al., 2008). To investigate 
whether the enhanced anxiety detected in the NAc-TMEM mice could response to the administration 
of anti-anxiety drugs, the mice were administered with diazepam (0.3 mg/kg i.p.) or vehicle 30 min 
before the elevated plus-maze and the light/dark box tests. The dose of diazepam for mice was 
referred to the previous study (Crestani et al., 1999), which would not affect anxiety-like behaviors 
in mice as a criticality. In the elevated plus-maze test, both the time spent in open arms (Fig. 9A, F(1, 
20) = 1.169) and the number of open arm entries (Fig. 9B, F(1, 20) = 5.2) were reduced in the 
NAc-TMEM mice when compared to the NAc-Mock mice, and this effect was reversed following 
the administration of diazepam (*p < 0.05). Similarly, in the light/dark box task, the time spent in the 
light box (Fig. 9C, F(1, 28) = 1.628) was markedly decreased in the NAc-TMEM mice compared to the 
NAc-Mock mice, and the enhanced anxiety in the NAc-TMEM mice was also reversed after the 
administration of diazepam (*p < 0.05). 
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Figure 9 Reversal of anxiety behaviors in the elevated plus-maze and light/dark box task following 
the administration of diazepam in the NAc-TMEM mice (A) and (B) Diazepam (0.3 mg/kg i.p.) or 
vehicle was administered 30 min before performance in the elevated plus-maze task. Number of 
entries and time on open arms were measured for 10 min in the elevated plus-maze task, N = 6; 
Values are presented as mean ± S.E.M. *p < 0.05 vs. NAc-TMEM (VEH) (two-way ANOVA 
followed by the Bonferroni’s post hoc tests). (C) Diazepam (0.3 mg/kg i.p.) or vehicle was 
administered 30 min before the light/dark box test. Time in the light box was measured for 10 min in 
the light/dark box test, N = 8; values are presented as mean ± S.E.M. *p < 0.05 vs. NAc-TMEM 
(VEH) (two-way ANOVA followed by the Bonferroni’s post hoc tests); VEH: vehicle administration 
group, DZP: diazepam administration group. 
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Sensorimotor gating deficit induced by TMEM168 overexpression in the NAc was reversed by 
the administration of risperidone 
Sensorimotor gating deficit, which is detected by auditory PPI test, is assumed to be a distinctive 
phenomenon of psychosis, including schizophrenia (Braff et al., 2001). Previous studies reported that 
antipsychotic drugs, such as risperidone, significantly reverse the low levels of sensorimotor gating 
(Ouagazzal et al., 2001). The NAc-TMEM mice and NAc-Mock mice were injected with risperidone 
(0.1 mg/kg i.p.) or saline 30 min before the auditory PPI test. The dose of risperidone administration 
was referred to the previous studies (Miyamoto et al., 2001; Mierzejewski et al., 2016), which would 
not affect locomotor activity and auditory startle response in mice. No differences were observed 
among each groups in the startle response to any pulse intensity, when the NAc-Mock and 
NAc-TMEM mice were administrated with saline or risperidone (Fig 10A, F(11, 162) = 0.6238). 
However, PPI was decreased at the prepulse of 74 dB and 78 dB in the NAc-TMEM mice  when 
compared with the NAc-Mock mice, and this impairment was reversed by the administration of 
risperdone (*p < 0.05, **p < 0.01, F(7, 108) = 2.293, Fig 10B).  
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Figure 10 Reversal of sensorimotor gating deficit in the PPI task following the administration of 
risperidone in the NAc-TMEM mice (A) Risperidone (0.01 mg/kg i.p.) or saline was administrated 
30 min before the task performance. Startle responses was measured at 70, 80, 90, 100, 110, and 120 
dB, respectively (background noise: 70 dB), N = 8; values are presented as mean ± S.E.M. (two-way 
ANOVA followed by the Bonferroni’s post hoc tests). (B) Risperidone (0.01 mg/kg i.p.) or saline 
was administered 30 min before the task performance. PPI was measured for 74, 78, 82, and 86 dB 
respectively, of prepulse intensity (background noise: 70 dB), N = 8; values are presented as mean ± 
S.E.M. *p < 0.05 vs. NAc-TMEM (VEH) (two-way ANOVA followed by the Bonferroni’s post hoc 
tests). VEH: saline administration group, RIS: risperidone administration group. 
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Overexpression of TMEM168 in the NAc decreased the basal levels of accumbal extracellular 
GABA and high K⁺-stimulated GABA levels in the NAc 
The contents of GABA and glutamate in the NAc were analyzed by HPLC. No differences in these 
contents were observed between the NAc-TMEM and NAc-Mock mice (Fig. 11A). The TMEM168 
overexpression inhibited the basal extracellular GABA levels in the NAc (p < 0.05; Fig. 11B). 
Moreover, elevated extracellular GABA levels following the high potassium stimulation (100 mM, 
15 min) was decreased in the NAc-TMEM mice when compared to the NAc-Mock animals (p < 0.01, 
F(6, 60) = 7.683; Fig. 11C). These results suggest that TMEM168 overexpression attenuated 
GABAergic neurotransmission in the NAc. 
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Figure 11 Inhibitory effects of TMEM168 on GABA neurotransmission in the NAc (A) Glutamate 
(GLU) and GABA concentrations in the NAc tissue were measured by HPLC. The NAc-Mock mice 
and NAc-TMEM mice were sacrificed and then the NAc tissue was extracted immediately, N = 10; 
values are presented as mean ± S.E.M. (B) Basal levels of extracellular GABA in the NAc were 
detected by the in vivo microdialysis task, N = 6; values are presented as mean ± S.E.M. *p < 0.05 vs. 
NAc-Mock (Student-t test). (C) Dynamic changes in the extracellular GABA levels in the NAc after 
high K⁺-stimulation was analyzed in the NAc by the in vivo microdialysis task, N = 6; values are 
given as mean ± S.E.M. **p < 0.01 vs. NAc-Mock. (ANOVA with repeated measures followed by 
the Bonferroni’s post-hoc test)  
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Inhibitory effects of the accumbal TMEM168 overexpression on the METH-induced 
hyperlocomotion and CPP 
Acute administration of METH (1 mg/kg, s.c.) induced an increase on locomotor activity in mice 
(p < 0.01). However, the METH-induced hyperlocomotion was slightly but significantly attenuated 
in the NAc-TMEM mice compared to the NAc-Mock mice (p < 0.01, F(1,1)=4.691) (Fig. 12A). In the 
CPP test, METH (1 mg/kg, s.c.) induced CPP in the NAc-Mock mice (p < 0.01). However, the 
METH-induced CPP was attenuated in the NAc-TMEM mice (p < 0.05, F(1,1)=3.356) (Fig. 12B). 
These results indicated that METH-induced dependence was attenuated by TMEM168 
overexpression in the NAc. 
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Figure 12 Inhibitory effect of TMEM168 on the METH-induced behavioral changes in NAc-TMEM 
mice compared to NAc-Mock mice (A) The locomotor activities in NAc-Mock mice and 
NAc-TMEM mice were measured for 60 min after METH administration (1 mg/kg, s.c.). Columns 
indicate means ± S.E.M.; n=9; **p < 0.01 vs saline group, ##p < 0.01 vs NAc-Mock (METH) 
(two-way ANOVA followed by the Bonferroni’s post-hoc test). (B) NAc-Mock mice and 
NAc-TMEM mice were trained for place preference for METH. Place preference data were 
expressed as the proportion of time spent in the drug-paired conditioning compartment. Columns 
indicate means ± S.E.M.; n=11; **p < 0.01 vs NAc-Mock (saline); #p < 0.05 vs NAc-Mock (METH) 
(two-way ANOVA followed by the Bonferroni’s post-hoc test). 
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Inhibitory effects of the accumbal TMEM168 overexpression on the METH-induced 
extracellular DA elevation in the NAc 
The basal levels of accumbal extracellular DA in the NAc-Mock and NAc-TMEM mice were 
analyzed by the in vivo microdialysis method. No significant differences between them were 
observed. After METH administration (1 mg/kg s.c.), extracellular DA levels in the NAc increased in 
the NAc-Mock mice, and these METH-induced elevation was attenuated in the NAc-TMEM mice (p 
< 0.01, F(1,10)=3.386) (Fig. 13A). Extracellular DA levels increased due to a high K
+
 stimulation (100 
mM, 15 min) in the NAc-Mock mice. The elevated DA levels were also inhibited in the NAc-TMEM 
mice (p < 0.01, F(1,14)=8.504) (Fig. 13B). These results indicated that the DA responses for neuronal 
activation in the NAc were inhibited by TMEM168 overexpression, by which the pharmacological 
action of METH was attenuated directly or indirectly. 
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Figure 13 Effects of TMEM168 overexpression on METH and high K
+
-induced extracellular DA 
elevation in the NAc of NAc-Mock mice and NAc-TMEM mice (A) No differences of extracellular 
DA basal levels in the NAc were detected between NAc-Mock mice, and NAc-TMEM mice. 
Dynamic changes in extracellular DA levels in the NAc after METH administration (1 mg/kg, s.c.) 
were calculated as a percent of basal levels. Values are mean ± S.E.M.; n=8; **p < 0.01 vs. 
NAc-Mock mice (two-way ANOVA with repeated measures followed by the Bonferroni’s post-hoc 
test). (B) Dynamic changes of extracellular DA levels in the NAc after high K
+
 stimulation (100 mM, 
15 min) were calculated as a percent of basal levels. Values are mean ± S.E.M.; n=4; **p < 0.01 vs. 
NAc-Mock mice (two-way ANOVA with repeated measures followed by the Bonferroni’s post-hoc 
test). 
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TMEM168 expressed in the Golgi apparatus and regulated extracellular OPN levels in COS-7 
cells 
The CMV-flag-TMEM168 plasmid vectors were transfected into COS-7 cells. To confirm the 
interaction of TMEM168 and OPN, immunoprecipitation analysis with anti-flag antibody is 
performed in the flag-TMEM168 transfected COS-7 cells. The TMEM-flag interacted with OPN in 
COS-7 cells (Fig. 14A). Moreover, both intracellular (p < 0.05) (Fig. 14B) and extracellular OPN 
protein levels (p < 0.01) (Fig. 14C) were detected to be increased by the flag-TMEM168 transfection. 
The expressional location of TMEM168 was also detected by immunostaining in the same cells. The 
result showed that TMEM168 expressed concentratedly beside the nucleus, which co-localized with 
the expression of Syntaxin 6 as the Golgi apparatus marker (Fig. 14D, 14E, 14F, 14G).  
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Figure 14 TMEM168-induced the enhancement of OPN in vitro and the localization of the 
overexpressed TMEM168 in the COS-7 cells (A) Interaction between TMEM168 and OPN in the 
COS-7 cells, which were transfected with flag-TMEM168, was confirmed by 
co-immunoprecipitation. The experiments were done 3 times, and the same results were obtained. 
(B) TMEM168 overexpression enhanced the intracellular OPN expression in the COS-7 cells. 
GAPDH was used as an internal control. Date are expressed as mean ± S.E.M.; n=5; *p < 0.05 vs. 
Mock group (Student-t test). (C) TMEM168 overexpression enhanced the extracellular OPN 
expression in COS-7 cells. Levels of extracellular OPN were analyzed by using ELISA. Results were 
normalized to the amount of media protein and were expressed as OPN per milligram protein. Date 
are expressed as mean ± S.E.M.; n=8; **p < 0.01 vs. Mock group (Student-t test). Localization of 
flag-TMEM168 and Syntaxin 6 in COS-7 cells was detected by immunostaining. (D) Overlapped 
images with flag-TMEM168, Syntaxin 6, and DAPI. (E) flag-TMEM168. (F) Syntaxin 6. (G) DAPI. 
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OPN enhancement was induced by TMEM168 overexpression and attenuated METH-induced 
hyperlocomotion and CPP in mice 
I fractionated the NAc tissues of the NAc-TMEM mice by using the Percoll gradient analysis. The 
expression pattern of Syntaxin 6 (Golgi apparatus marker) and GAPDH (cytosol marker) was similar 
to a previous study (Hara-Kuge et al., 2004), which indicated that the Golgi apparatus-consisted 
fraction was isolated successfully from the NAc tissues. The majority of TMEM168 and OPN were 
detected in this Syntaxin 6-positive fraction, compared to other fractions (Fig. 15A). Total OPN 
protein levels in the NAc increased about 1.5 ± 0.17 folds (p < 0.05) (Fig. 15B) in the NAc-TMEM 
mice, compared to NAc-Mock mice. Furthermore, the bilateral intra-injection of OPN (0.03 μg/side) 
did not affect spontaneous locomotor activity in wild-type mice. However, METH-induced 
hyperlocomotion (p < 0.01) was attenuated in the OPN administration group, compared to the 
vehicle administration group (p < 0.01, F(1,1)=22.64) (Fig. 15C). Similarly, the bilateral 
intra-injection of OPN (0.03 μg/side) did not induce CPP in wild-type mice, However, 
METH-induced CPP (p < 0.01) was attenuated in the OPN administration group, compared to the 
vehicle administration group (p < 0.01, F(1,1)=5.631) (Fig. 15D). 
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Figure 15 Interaction with TMEM168 and OPN in the Golgi and the inhibitory effect of OPN on 
METH-induced behavioral changes (A) Co-expression of TMEM168 and OPN in the Golgi 
consisted of a fraction separated from four TMEM168 overexpressed NAc tissue, detected by the 
Percoll gradient analysis. The experiments were done 3 times and the same results were obtained. (B) 
Accumbal OPN expression in the NAc-Mock mice and NAc-TMEM mice was detected by western 
blotting. GAPDH was used as an internal control. Date are expressed as mean ± S.E.M.; n=6; *p < 
0.05 vs. NAc-Mock mice (Student-t test). (C) OPN protein (0.03 μg/0.25 μL/side) was intra injected 
bilaterally before the administration of METH (1 mg/kg s.c) or saline (s.c.) and then locomotor 
activity tests were carried out immediately. The locomotor activity was measured for 60 min. 
Columns indicate means ± S.E.M.; n=5; **p < 0.01 vs saline group, ##p < 0.01 vs vehicle (METH) 
(two-way ANOVA followed by the Bonferroni’s post-hoc test). (D) Time spent in each compartment 
was measured for 15 min on the preconditioning test day and the postconditioning test day. Place 
preference data was expressed as the proportion of time spent in the drug-paired conditioning 
compartment. Columns indicate means ± S.E.M.; n=6-8; *p < 0.05, ** p < 0.01 vs saline group, ##p 
< 0.01 vs vehicle (METH) (two-way ANOVA followed by the Bonferroni’s post-hoc test). 
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Discussion 
The alteration of gene expression after psychostimulant exposure is an important mechanism that 
underlies the drug-induced adaptive changes in the brain, and results in the modulation of behavioral 
impairments in drug dependence (Nestler, 2012). As the NAc is a key region of the rewarding system 
in the brain (Russo and Nestler, 2013), the accumbal molecules of which the mRNAs expression are 
sensitive to respond to METH stimulation in mice were analyzed by the PCR-selected cDNA 
subtraction method. As a result, TMEM168 mRNA was observed to increase in the NAc after 
repeated METH administration. Furthermore, TMEM168 is suggested to be a transmembrane protein 
in the Golgi apparatus. The increased TMEM168 inhibited GABAergic neurotransmission in the 
NAc, and then induced anxiety in the elevated plus-maze and light/dark box tests as well as the 
sensorimotor gating deficit in the auditory PPI test. Moreover, the increased TMEM168 enhanced 
OPN expression in the NAc, and inhibited METH-induced behavioral changes, such as 
hyperlocomotion and CPP, by controlling dopaminergic neuronal activities in the NAc. The results of 
the present study suggest that TMEM168 serves as an adaptive molecule to regulate OPN signaling, 
which functions to ameliorate the abnormal neurotransmission after toxic METH exposure. 
Extracellular DA in the NAc is released from the dopaminergic terminal, which projects from the 
VTA (Russo and Nestler, 2013; Groenewegen et al., 1999). The accumbal microinjection of 
AAV-TMEM168 vectors transduces into the local neurons preferentially (Davidson et al., 2000; 
Tenenbaum et al., 2004). Hence, the AAV vector-induced TMEM168 overexpression would affect 
the functions of local neurons in the NAc directly; following this, the projected dopaminergic 
activity would be influenced by some extracellular mediators in the NAc indirectly. The synaptic 
cleft between the neuronal cells consists of the extracellular matrix (ECM) (Zimmermann and 
Dours-Zimmermann, 2008). The ECM plays an important role in regulating neuronal plasticity and 
psychostimulant-induced addictive changes (Dityatev et al., 2010; Gundelfinger et al., 2010; Lubbers 
et al., 2014). OPN is a member of the ECM family (Wang and Denhardt, 2008), and it has been 
demonstrated to interact with TMEM168 by the yeast two-hybrid analysis (Long et al., 2012). In the 
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present studies, the association with TMEM168 and OPN was confirmed by the in vitro 
immunoprecipitation analysis. Moreover, extracellular and intracellular OPN increased in vitro in the 
flag-TMEM168-transfected COS-7 cells. Similar increase of OPN levels was observed in vivo, in the 
NAc of the NAc-TMEM mice. Furthermore, intra-accumbal infusion of the OPN protein attenuated 
METH-induced hyperlocomotion and CPP, indicating that the elevated extracellular OPN in the NAc 
participates in the inhibitory effect of TMEM168 on the METH-induced behavioral changes. Thus, 
OPN could be one candidate mediator for the TMEM168 overexpressed local cells to affect the 
projected dopaminergic terminal in the NAc, which inhibited the METH-induced dependence.  
The alternative splicing of OPN mRNA generates two types of protein, the intracellular form and 
the secretory form of OPN (Shinohara et al., 2008). Intracellular OPN remains inside the cells; 
alternatively, secretory OPN is packaged in the Golgi apparatus, and then is transported into 
secretory vesicles, resulting in its secretion from the cells to the extracellular space in synaptic cleft 
(Shinohara et al., 2008; Cantor and Shinohara, 2009). The co-localization of TMEM168 and OPN in 
the Golgi apparatus marker Syntaxin 6-consisted fraction was detected via the immunostaining and 
Percoll gradient analysis. Thus, TMEM168 is identified as a transmembrane protein in the Golgi 
apparatus. OPN secretion could be activated by TMEM168 overexpression, via affecting the 
trans-Golgi network process in the cells. 
According to previous studies, two possibilities are presumed to clarify the downstream processes 
of the activated OPN signaling of the drug exposure. One possibility is that the integrin receptors 
might work as an OPN downstream pathway to control addictive effects. Extracellular OPN interacts 
with αvβ1, αvβ3, αvβ5, and α8β1 integrin receptors via an arginine-glycine-aspartate (RGD) 
sequence consisted in the protein (Uede, 2011). The intraaccumbal injection of the RGD peptide 
attenuates the relapse to cocaine-seeking behavior (Wiggins et al., 2011), and the expression of 
integrin β1 subunit levels decrease, whereas β3 subunit levels increase, in the NAc after cocaine 
administration (Wiggins et al., 2009; Wiggins et al., 2011). It is suggested that the 
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RGD/OPN-integrin signaling pathway underlie the inhibition of psychostimulant impairment. 
Accordingly, the TMEM168-OPN pathway might control the response of the rewarding system in 
the NAc via the RGD sequence and integrin receptors. Another possibility is the interaction between 
matrix metalloproteinase (MMP) and OPN. As one of the ECM proteins, OPN is cleaved by 
MMP-2,-3,-7 and/or -9, which results in structural and functional changes in the brain via the 
MMP-induced mediated cleavage (Agnihotri et al., 2001; Dean and Overall, 2007; Stamenkovic, 
2003; Takafuji et al., 2007). Recently, MMP-2 and MMP-9 were reported to be required for the 
induction of behavioral changes in cocaine relapse and METH-induced dependence, and to regulate 
glutamatergic transient synaptic potentiation and dopaminergic functions in the NAc (Mizoguchi et 
al., 2007; Smith et al., 2014; Smith et al., 2016). Although the functional mechanism of MMPs in the 
NAc remains to be established, our studies indicate that the TMEM168-regulated OPN system 
become a related event for the addictive effect of MMPs. 
It is an interesting result that extracellular OPN levels are related to METH-induced dopaminergic 
hyperfunction. Previous studies have suggested the relationship between OPN and the nigrostriatal 
dopaminergic pathway. OPN is elevated in the substantia nigra of the Parkinson's disease patients 
(Iczkiewicz et al., 2006), and the interaction of OPN with integrin and CD44 receptors in the 
substantia nigra plays a role in the neuroprotective effect in the Parkinson’s disease animal models 
(Ailane et al., 2013). However, no previous studies have indicated that OPN controls the mesolimbic 
dopaminergic pathway, which is involved in the rewarding system. As METH is an addictive and 
neurotoxic psychostimulant, the administration of METH leads to monoaminergic neuronal damage, 
such as neuroinflammation, in humans and rodents (Northrop and Yamamoto, 2015). OPN might 
play a role in the endogenous neuroprotective response, such as anti-inflammatory and anti-oxidant 
effect after the toxic insults in the brain (Ailane et al., 2013; Inoue and Shinohara, 2015; Scott et al., 
1998; Kahles et al., 2014). Although the relationship between TMEM168 and METH toxicity is still 
unclear, our group demonstrates that the overexpressed TMEM168 and OPN in the NAc attenuate 
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METH-induced dependence.  
It should be noted that the present results can’t exclude the possibility of other parallel 
TMEM168-related pathways that underlie the inhibitory effect of TMEM168 on METH-induced 
dependence. Despite TMEM168-regulated OPN signaling is proved to be one effective inhibitory 
mechanism on METH-induced pharmacological effect. There are still some critical questions 
remaining to be clarified in the future. For example, although the inhibited GABAergic 
neurotransmission in the NAc would underlie the increased anxiety in the NAc-TMEM mice, the 
mechanism of TMEM168 influencing GABAergic activity remains to be studied. Additionally, it is 
difficult to explain the etiology of sensorimotor gating deficit induced by TMEM168 overexpression 
in the NAc. Moreover, the questions that what is the detailed function of TMEM168 in the 
trans-Golgi network process to increase OPN secretion, and how does the TMEM168-activated OPN 
downstream pathway to regulate extracellular DA in the NAc, are still unclear.  
In summary, in the present chapter, TMEM168 overexpression actives the OPN signaling, and 
then METH-induced pharmacological actions are attenuated by regulating the dopaminergic function 
in the NAc (Fig. 16). Thus, our observations indicate that TMEM168-regulated OPN system is a 
promising novel target for the therapy of METH dependence. 
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Figure 16 The summary of chapter 1. When the AAV vector was injected, the function of the NAc 
was affected. The AAV-TMEM168 vector increased TMEM168 mRNA in the local neurons of the 
NAc, and TMEM168 was increased in the Golgi apparatus. TMEM168 interacted with OPN, and 
then extracellular OPN was increased. At the same time, the METH-induced dopamine elevation was 
attenuated. As the result, the METH-induced CPP and hyperlocomotion were inhibited. 
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CHAPTER 2 
Therapeutic effect of PF11 on METH-induced dependence via regulating accumbal GABAergic 
and opioidergic neuronal system in mice 
 
Introduction 
American ginseng (Panax quinquefolius) originates from the northern region of the United States. 
It is a popular medicinal plant and its root is commercially used as a nutritional supplement. Most of 
the active constituents in American ginseng , such as ginsenosides (Ra, Rb, Rc, Rd, Re, and Rg)， are 
similar to those in other ginseng species, including Asian ginsengs (Li et al. 2010). However, several 
minor constituents, such as pseudoginsenoside-F11 (PF11) (Fig. 17), are reported that exist only in 
American ginseng (Li et al. 2010). Owing to the special existence of PF11 compared to other active 
constituents, many pharmacological studies about PF11 were performed according to the therapeutic 
effect of American ginseng in traditional medicine. As a result, PF11 is shown to be an ocotillol-type 
saponin that acts as a neuroactive compound. Pretreatment with PF11 (4 and 8 mg/kg, p.o.) inhibits 
morphine-induced locomotor sensitization and CPP, and prevents memory impairment and analgesia 
induced by morphine (Li et al. 2000). Additionally, PF11 also inhibits affinity of morphine for 
μ-opioid receptors (with an IC50 of ~approximately 6.1 μM), and decreases the morphine-induced 
inhibition of intracellular cAMP production in Chinese hamster ovary cells (Li et al. 2001). This 
study suggests that PF11 may serve as an antagonist of μ-opioid receptors potentially. Moreover, PF11 
shows protective effects on scopolamine-induced memory deficits (Li et al. 1999), and indicates 
anti-amnesic effects in Alzheimer’s disease model mouse (Wang et al. 2013). METH-induced 
toxicity in mice, including memory impairment and behavioral despair, is also improved by PF11 
pretreatment (Wu et al. 2003). However, it is still unclear that whether PF11 is effective on 
METH-induced dependence and dopaminergic neuronal system in the NAc. 
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According to previous studies, the associations between amphetamines and opioid receptor 
systems have been demonstrated. Co-administration of morphine and METH can strengthen the 
METH-induced hyperlocomotion significantly (Trujillo et al. 2011). On the other hand, naloxone, a 
non-selective opioid receptor antagonist, inhibits amphetamine-induced DA elevation and behavioral 
hyperactivity (Feigenbaum and Howard 1997; Chiu et al. 2005; Schad et al. 2002). Additionally, 
administration of the specific μ-opioid receptor antagonist naloxonazine reverses acute 
METH-induced increases in locomotor activity and attenuates the expression levels of DARPP-32 
(dopamine- and cyclic AMP-regulated phosphoprotein of Mr 32,000) (Chien et al. 2012). Moreover, 
when the μ-opioid receptor is knockout in mice, the METH-induced behavioral changes, such as 
hyperlocomotion and stereotypy are inhibited (Shen et al. 2010).  
Given the pharmacological opioid-antagonistic properties of PF11, we presumed that PF11 might 
become an effective compound for METH-induced dependence. Thus, the present study investigated 
that whether PF11 would inhibit pharmacological actions of METH. Behavioral tests were performed 
in mice after the administration of PF11, and the inhibitory effects were observed on the 
METH-induced locomotor sensitization and CPP. Similarly, METH-induced extracellular DA 
elevation was also attenuated by repeated pretreatment of PF11. Furthermore, the GABAergic 
neurotransmission in the NAc was elevated after repeated PF11 administration. As the accumbal 
μ-opioid receptors mainly express in the local GABA interneurons of the NAc (Svingos et al. 1997), 
the effect of PF11 on μ-opioid receptors were confirmed by behavioral tests to elucidate the 
mechanism by which the influences of PF11 on the GABAergic neuronal systems controls 
METH-induced dependence. 
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Figure 17 Structural formula of pseudoginsenoside-F11 (PF11). 
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Materials and Methods 
 
Animals 
Male ICR mice (Nihon SLC, Inc. Hamamatsu, Japan) were housed in a room with a 12 h light/dark 
cycle (8 am–8 pm). At the beginning of the experiments, the mice were 8–week–old and weighed 
22–27 g. All procedures followed the National Institute of Health Guideline for the Care and Use of 
Laboratory Animals and were approved by the Animal Experiments Committee of the University of 
Toyama (Permit Number A2012PHA-31). 
 
Drugs 
METH was purchased from Dainippon Sumitomo Pharmaceutical Co. Ltd. (Osaka, Japan), and was 
dissolved in saline (0.9% NaCl) (0.1 mg/mL). D-Ala
2
,N,Me-Phe
4
,Gly-ol
5
-enkaphalin acetate salt 
(DAMGO, Sigma–Aldrich Co.) was dissolved in sterile saline for the intra-injection in locomotor 
activity test, and was dissolved in ringer’s solution (147 mM NaCl, 4 mM KCl, and 2.3 mM CaCl2) 
for the infusion in microdialysis test. Pseudoginsenoside-F11 (PF11) was isolated from aerial parts of 
Panax quinquefolius by the Department of Natural Products Chemistry, Shenyang Pharmaceutical 
University Shenyang, China, and was dissolved in saline at 0.4 or 0.8 mg/mL. PF11 was isolated 
according to previously described methods (Besso et al. 1982), and a purity of >98% was confirmed 
using HPLC. All other reagents were obtained from standard commercial sources. 
 
CPP test 
The CPP test was performed according to the described method in the previous section. The 
procedure schedule was shown in Figure 18. PF11 or saline treatment was administrated one hour 
before METH administration. In the METH-induced withdrawal test, the experiment was designed 
according to previous studies with minor modifications (Niwa et al. 2007b; Miyamoto et al., 2014). 
After post-conditioning test on day 10, PF11 (8 mg/kg/day p.o.) was administrated to mice for 5 days 
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and on day 16, the post-conditioning test was performed for the second time which was also 
measured for 15 min (Fig 19). The CPP behaviors were expressed as Post–Pre values, which were 
calculated as [(post value) − (pre value)] to reflect the difference in time spent in METH and 
saline-conditioning sides in post and pre-conditioning stages, respectively. 
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Figure 18 Dosing and testing protocol for CPP analyses; Mice received METH (1 mg/kg s.c.) or 
saline injections 1 hour after PF11 (1, 4, 8 mg/kg, p.o.) or saline treatments. 
 
 
 
 
 
 
 
 
 
 
Figure 19 Dosing and testing protocol for CPP analyses; after the first post-conditioning test, mice 
were administered PF11 (8 mg/kg, p.o.) for 5 days without METH treatment and the next day the 
place preference was tested for the 2
nd
 post-conditioning.  
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Locomotor Activity test 
Locomotor activity test was performed according to the described method in the previous section. 
Locomotion of the mice was measured every 5 min for 60 min using digital counters with infrared 
sensors (Scanet MV-40; MELQEST, Toyama, Japan). Mice were continuously administered METH 
(1 mg/kg s.c.) or saline 1 hour after PF11 (4 and 8 mg/kg p.o.) treatment for 6 days, and locomotor 
activity was measured immediately after METH or saline administration on days 1, 3, and 6.  
In DAMGO-induced locomotor test, PF11 (8 mg/kg p.o.) was pretreated 1 hour before the 
intra-injection of DAMGO (0.0025 μg/0.5 μL/side into the NAc), and then locomotor activity was 
measured for 1 hour immediately. 
 
Intra-accumbens injection procedures 
Intra injection was performed according to the described method in the previous section. DAMGO 
(0.0025 μg) or saline were infused in a total volume of 0.5 μL/side at a rate of 0.25 μL/min using a 
microdrive pump (ESP-64; Eicom), and injectors were left in the NAc for an additional 30 seconds 
to allow for diffusion after the 2 min infusion period.  
 
In vivo Microdialysis and HPLC detection 
The procedures in in vivo microdialysis analyses and HPLC detection were performed according to 
the described method in the previous section. In the DA analysis by using DAMGO, PF11 or saline 
was administrated 4 h after the probe insertion, and then 1 h later DAMGO (0.1 mM) was infused for 
15 min. 
 
Statistical Analyses 
All data were expressed as the mean ± S.E.M. Pairwise differences between groups were determined 
using Student’s t test, and multiple group comparisons were performed using one-way ANOVA 
followed by Student–Newman–Keuls post-hoc tests for differences with significant F ratios (p < 
0.05). Statistical analyses of locomotor sensitization and in vivo microdialysis experiments were 
57 
 
performed using repeated measures two-way ANOVA followed by Bonferroni’s post-hoc tests (Prism 
version 5). 
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Results 
 
PF11 attenuates the development of METH-induced CPP 
In the CPP paradigm, the experimental schedule is described in Figure 18. In the saline–METH 
treated mice, CPP was induced by METH (1 mg/kg, s.c.), with a 3.7 ± 1.74 folds increase compared 
to the saline–saline treated mice (#p < 0.01). Pretreatment with PF11 (4 and 8 mg/kg, p.o.) attenuated 
the METH-induced CPP, with 6.5 ± 1.50 and 4.4 ± 1.04 folds decrease respectively (
*
p < 0.05). 
These results suggest that PF11 attenuates the development of the METH-induced CPP (Fig. 20; F(4,50) 
= 3.077). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 PF11 attenuated the development of METH-induced CPP. Place preference data were 
expressed as the proportion of time spent in the drug-paired conditioning compartment. Columns 
indicate means ±S.E.M. from 11 mice; F(4,50) = 3.077; #p < 0.01 for the saline+saline group; *p < 
0.05 for the saline+METH group. 
 
 
59 
 
PF11 attenuates developed METH-induced CPP 
In the second CPP paradigm, the experimental schedule is described in Figure 19. After 
development of METH-induced CPP in the 1
st
 post-conditioning test (Fig 21; 
$
p < 0.05 compared to 
the saline group), mice were treated with PF11 (8 mg/kg, p.o.) for 5 days without METH. Following 
this, the 2
nd
 post-conditioning test was performed. The METH-induced CPP was still maintained in 
vehicle-treated METH withdrawal mice (
#
p < 0.05 compared to saline–vehicle group). However, 
administration of PF11 for 5 days reversed the developed METH-induced CPP, with a 2.5 ± 0.80 folds 
decrease in Post–Pre values compared to the METH–vehicle group at the 2nd post-conditionings test 
(Fig 21; 
*
p < 0.05; F(3,40) = 9.088). 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 After the dovelopment of METH-induced CPP, repeated administration of PF11 inhibited 
the developed METH-induced CPP. Place preference data were expressed as the proportion of time 
spent in the drug-paired conditioning compartment. Columns indicate means ± S.E.M. from 6 mice; 
F(3,40) = 9.088; #p < 0.01 for the saline+saline group; *p < 0.05 for the saline+METH group. 
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Repeated PF11 administration inhibits METH-induced locomotor sensitization 
Single METH administration (1 mg/kg, s.c.) induces hyperlocomotion in mice, and pretreatment 
with PF11 (4 or 8 mg/kg, p.o.) only onece did not change METH-induced hyperlocomotion in mice 
on day 1 (Fig. 22A; F(3,33) = 4.982). However, repeated PF11 administration 1 h before the METH 
treament every day inhibited METH-induced locomotor sensitization on day 3 and day 6 (Fig. 22B, 
F(3,33) = 2.211; Fig. 22C, F(3,33) = 3.948; and Fig. 22D, F(3,6) = 5.367; 
*
p < 0.05,
 **
p < 0.01, 
saline+METH vs. saline+saline group; 
#
p < 0.05, 
##
p < 0.01, PF11 4+METH vs. saline+METH 
group; 
&
p < 0.05, 
&&
p < 0 .01, PF11 8+METH vs. saline+METH group).  
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Figure 22 Repeated PF11 administration inhibited METH-induced locomotor sensitization. Mice 
were administered PF11 (1, 4 or 8 mg/kg, p.o.) or saline 1 hour before METH (1 mg/kg, s.c.) or saline 
treatments once a day for 6 days, and locomotor activity was tested for 1 hour immediately after 
METH administration on days 1, 3, and 6. Locomotor activity is expressed as activity counts per 5 
min for 60 min on (A) day 1, (B) day 3, and (C) day 6. (D) Total locomotor activity counts for 60 
min on days 1, 3, and 6; Lines and columns indicate means ± S.E.M. (n = 13); (A) F(3,33) = 4.982, (B) 
F(3,33) = 2.211, (C) F(3,33) = 3.948, (D) F(3,6) = 5.367; 
*
p < 0.05, 
**
p < 0.01, saline+METH vs. 
saline+saline group; 
#
p < 0.05, 
##
p < 0.01, PF11 4+METH vs. saline+METH group; 
&
p < 0.05, 
&&
p < 
0 .01, PF11 8+METH vs. saline+METH group. 
 
C 
B 
D 
A 
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Repeated PF11 administration attenuates METH-induced extracellular DA increase in the NAc 
of mice 
We investigated the extracellular DA levels in the NAc after repeated co-administration of PF11 
and METH for 6 days. Repeated co-administration of PF11 (4 and 8 mg/kg, p.o.) and METH (1 
mg/kg, s.c.) significantly attenuated METH-induced extracellular DA elevation in the NAc of mice 
on day 7. On the other hand, repeated administration of PF11 (8 mg/kg, p.o. for 7 days) without 
METH did not influence extracellular DA levels compared to the saline treated group on day 7 (Fig. 
23; F(4,42) = 6.315, 
**
p < 0.01, saline+METH vs. saline+saline group; 
##
p < 0.01, PF11 4+METH vs. 
saline+METH group; 
&&
p < 0 .01, PF11 8+METH vs. saline+METH group). 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 Repeated pretreatments with PF11 attenuated METH-induced increase in extracellular DA 
levels in the NAc. Microdialysis data are expressed as percentages of baseline DA levels. PF11 was 
administered at 4 and 8 mg/kg, p.o. 60 min before subcutaneous injections of METH (1 mg/kg) or 
saline for 6 days. In vivo microdialysis analyses were performed on day 7. Lines represent mean ± 
S.E.M. (n = 4); F(3,42) = 6.315; 
**
p < 0.01, saline+METH vs. saline+saline group; 
##
p < 0.01, PF11 
4+METH vs. saline+METH group; 
&&
p < 0.01, PF11 8+METH vs. saline+METH group. 
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Repeated PF11 administration increases extracellular GABA levels in the NAc 
Repeated co-administration of PF11 and METH led to significant increase in extracellular GABA 
levels in the NAc, whereas METH alone (1 mg/kg/day, s.c. for 7 days) did not. Furthermore, PF11 
was administered repeatedly without METH (8 mg/kg/day, p.o.) for 7 days and extracellular GABA 
levels in the NAc were observed to increase gradually (Fig. 24; F(4,28) = 3.176, 
**
p < 0.01, PF11 
8+METH vs. saline+METH;
 #
p < 0.05, 
##
p < 0.01, PF11 4+METH vs. saline+METH group; 
&
p < 
0.05, PF11 8+saline vs. saline+saline group). These results suggest that repeated PF11 administration 
increases GABA levels in the NAc, independently of METH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 Repeated administration of PF11 with or without METH increased extracellular GABA 
levels in the NAc. Microdialysis data are expressed as percentages of baseline GABA levels. PF11 (4 
and 8 mg/kg, p.o.) was intragastrically administered 60 min before subcutaneous injections of METH 
(1 mg/kg) or saline for 6 days. In vivo microdialysis analyses were performed on day 7. Lines 
represent mean ± S.E.M. (n = 4); F(4,28) = 3.176; 
**
p < 0.01, PF11 8+METH vs. saline+METH; 
#
p < 
0.05, 
##
p < 0.01, PF11 4+METH vs. saline+METH group; 
&
p < 0.05, PF11 8+saline vs. saline+saline 
group. 
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Single PF11 administration do not affect extracellular GABA levels in the NAc 
Although repeated PF11 administration elevated extracellular GABA levels in the NAc (Fig 24), 
single administration of PF11 or METH did not affect GABA levels in the NAc (Fig. 25, F(2,14) = 
1.242). 
 
 
 
 
 
 
 
 
 
Figure 25 Single treatments with PF11 or METH did not affect extracellular GABA levels in the 
NAc. Microdialysis data are expressed as percentages of baseline GABA levels. Four hours after 
probe insertion, PF11 (8 mg/kg, p.o.) or METH (1 mg/kg, s.c.) were administered in a single dose. 
The last two samples before drug administered were used to indicate baseline GABA levels. Lines 
represent means ± S.E.M. (n = 3) and the vehicle group comprised 4 mice; F(2,14) = 1.242. No 
significant effects of METH or PF11 were observed. 
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Pretreatment of PF11 inhibits accumbal DAMGO intra-injection -induced hyperlocomotion 
The bilateral intra-injection of μ-opioid receptor agonist DAMGO (0.0025 μg/0.5 μL/side) 
induced hyperlocomotion with an increase of 1.8 ± 1.17 folds compared to the saline–saline group 
(Fig. 26; 
#
p < 0.01). Pretreatment of PF11 (8 mg/kg, p.o.) at 1 hour before the DAMGO 
intra-injection attenuated the  DAMGO-induced hyperlocomotion with a decrease of 1.9 ± 0.76 
folds compared to saline–DAMGO group (Fig. 26; *p < 0.01; F(2,9) = 9.555). 
 
 
 
 
 
 
 
 
 
 
Figure 26 Pretreatment with PF11 inhibited DAMGO-induced hyperlocomotion. Guide cannula was 
implanted in the bilateral NAc and were allowed 48 hours to recover from surgery. PF11 (8 mg/kg, 
p.o.) or saline was administrated 1 hour before DAMGO (0.0025 μg/0.5 μl/side) or saline 
intra-injection. The locomotor activity was tested for 1 hour immediately after DAMGO infusion. 
Locomotor activity is expressed as activity counts for 60 min. Columns indicate means ± S.E.M. 
from 4 mice; F(2,9) = 9.555; 
*
p < 0.01,  PF11–DAMGO vs. saline–DAMGO group; #p < 0.01, saline–
DAMGO vs. control group. 
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Pretreatment of PF11 attenuates DAMGO-induced extracellular DA elevation in the NAc 
Infusion of DAMGO (0.1 mM; 0.5 μL/min) for 15 min increased the accumbal extracellular DA 
levels significantly (Fig. 27). Pretreatment of PF11 at 1 h before the DAMGO infusion reversed the 
DAMGO-induced DA elevation in the NAc (Fig. 27; 
*
p < 0.01; F(1,17) = 5.813). 
 
 
 
 
 
 
 
 
 
 
Figure 27 Pretreatments with PF11 attenuated DAMGO-induced increase in extracellular DA levels 
in the NAc. Microdialysis data are expressed as percentages of baseline DA levels. PF11 (8 mg/kg, 
p.o.) or saline was administered 60 min before perfusion of DAMGO (0.1 mM in aCSF for 15 min). 
Lines represent mean ± S.E.M. (n = 4); F(1,17) = 5.813; 
*
p < 0.01, PF11–DAMGO vs. saline–DAMGO 
group. 
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Discussion 
Psychiatric responses, including hyperlocomotion and locomotor sensitization, are commonly 
revealed in METH-induced dependence (Grant et al. 2012). METH-induced CPP is also usually 
performed in animals as a method to assess the psychoactive effects of METH on behaviors (Niwa et 
al. 2007a). In the present study, the effects of PF11 on METH-addicted mice by locomotor activity 
test and CPP test were investigated. Our results indicate that repeated administration of PF11 inhibits 
METH-induced locomotor sensitization and CPP. Moreover, only PF11 administration showed no 
significant effects on locomotor activity and CPP tests, according to the previous study in Li et al. 
2000. It is suggested that the treatment of PF11 has a therapeutic effect on the behavioral alterations 
induced by METH, and does not have side effects on normal behaviors. 
The enhancement of dopaminergic neurotransmission in the NAc is known to be involved in 
amphetamine-induced hyperlocomotion (Iversen et al. 1975; Pijnenburg et al. 1976). Similarly, the 
regulation of dopaminergic functions in the NAc is considered to underlie CPP behaviors (Miyamoto 
et al., 2014). Hence, the effect of PF11 on dopaminergic neuronal systems in the NAc was 
investigated in order to further elucidate the inhibitory mechanisms of PF11 on METH-induced 
behavioral alterations in mice. In vivo microdialysis analysis is a useful tool to detect the levels of 
extracellular neurotransmitters in a specific brain region, and it is widely used to assess the 
pharmacological effects on METH dynamics (Sabol et al. 2001). In this study, repeated 
co-administration of METH and PF11 normalized the elevated DA levels in the NAc compared to the 
repeated METH-administrated mice. Moreover, PF11 alone without METH did not affect 
extracellular DA levels which were similar to the saline treated control group. These results of DA 
dialysis were consistent with the inhibitory effect of PF11 on behavioral events in our present 
experiment. Thus, the normalized extracellular DA in the NAc indicates the neurochemical effect of 
PF11 on the attenuated METH addiction in mice. 
Although no previous studies can directly explain how PF11 reverses METH-induced accumbal 
DA elevation, there is a possibility that the dopaminergic neuronal systems can be influenced by PF11 
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via its inhibitory effect on μ-opioid receptors. In order to confirm this conjecture, firstly the 
experimenter investigated the pharmacological effect of PF11 on the behavioral and neurochemical 
responses by using a μ-opioid receptor agonist DAMGO. Intra accumbal infusion of DAMGO 
increases locomotor activity (Katsuura et al. 2010; Parker et al. 2015), and also elevates extracellular 
DA levels in the NAc (Hipólito et al. 2008; Hirose et al. 2005). Systemic administration of μ-opioid 
receptor antagonists also attenuates DA elevation induced by μ-opioid receptor agonist infusion 
(Okutsu et al. 2006). In the present experiments, PF11 pretreatment reversed DAMGO-induced 
hyperlocomotion and accumbal DA elevation. It is suggested that PF11 shows, at least a part, 
antagonism to the μ-opioid receptors in the NAc. 
Opioidergic neuronal systems, including μ-opioid receptors, have been identified as important 
regulator for the pharmacological actions of psychostimulants in the mesolimbic DA system (Contet 
et al. 2004; Devine et al. 1993; Feigenbaum and Howard 1997; Schad et al. 1996; Schad et al. 2002). 
Relationships between the opioid neuronal system and psychostimulant-induced DA elevation have 
been investigated in several previous reports. For example, intra-perfusions of the non-selective 
μ-opioid receptor antagonist naloxone in the VTA significantly reversed the amphetamine-induced 
DA elevation in the NAc (Schad et al. 2002). Moreover, systemic administration of naloxone (5 
mg/kg) shows inhibitory effect on the amphetamine-induced DA elevation in the striatum 
(Feigenbaum and Howard 1997). These studies support our hypothesis that PF11 reverses the 
pharmacological actions of METH by its antagonized effect on μ-opioid receptors. 
The μ-opioid receptors are mainly expressed on GABA neurons in the brain, including the NAc 
(Svingos et al. 1997), and the functions of these receptors play an important role to regulate 
dopaminergic neurotransmission by inhibiting GABA release (Contet et al. 2004). Elevated 
GABAergic neurotransmissions attenuate endogenous DA release (Dewey et al. 1992). In the NAc, 
the GABA interneurons are observed to synapse on the dopaminergic projections from the VTA 
(Tepper and Bolam, 2004). Blockade of the μ-opioid receptors on the GABA interneurons can cause 
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a disinhibition of GABA release in the NAc, and then lead to the attenuation of accumbal DA release 
during METH exposure. As discussed above, PF11 has antagonized effect on μ-opioid receptors. 
Furthermore, repeated administration of PF11 increased extracellular GABA levels in the NAc. Hence, 
it is suggested that repeated PF11 administration can affect the functions of GABA interneurons in the 
NAc, and promote GABA release. Thus, the repeated administrated PF11 attenuated the functions of 
μ-opioid receptors on the GABA neurons, and then GABAergic activity was increased by 
disinhibition. As a result, METH-induced accumbal DA elevation and behavioral abnormalities were 
inhibited (Fig 28). 
Execpting the GABA interneurons in the NAc, those in the VTA, which regulate the dopaminergic 
projection to the NAc locally (Bocklisch et al., 2013), might also act as an important regulator for  
the accumbal DA modulation during the treatment of PF11. However, owing to the small size of the 
VTA in mice, extracellular GABA levels in the VTA was not detectable by using in vivo 
microdialysis analysis. Thus, I could not exclude the possibility that the VTA GABAergic functions 
may be influenced by PF11. However, additional studies are required to clarify this question in the 
future. 
In summary, our studies demonstrate that PF11 is an effective compound to attenuate the 
METH-induced dependence in mice by controlling extracellular DA levels in the NAc. PF11 can 
facilitate the GABA release in the NAc of the METH-addicted mice. The present findings indicate 
the potential role of the ocotillol-type saponin PF11 in the medical treatment of METH-induced 
dependence. 
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Figure 28 The summary of chapter 2. After co-administration of PF11 and METH, the function of the 
NAc was affected. The opioid neuronal system in the NAc was affected by PF11 directly or indirectly. 
Subsequently, accumbal extracellular GABA was increased gradually. Thus METH induced 
dopamine efflux in the NAc was attenuated, and the METH-induced CPP and locomotor 
sensitization were inhibited. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
TMEM168 is analyzed to express highly in the brain compared to other organs, and mainly 
express in neurons. It is a transmembrane protein located in the Golgi apparatus and regulates 
trans-Golgi network. After the AAV-TMEM168 vector microinjection, anxiety and sensorimotor 
gating deficit were observed with a decrease of GABA in the NAc. The overexpressed TMEM168 
interacted with OPN, and subsequently facilitated the secretion of OPN. The increased extracellular 
OPN served as a mediator to affect the projected DA synapse. Thus, when METH was administrated, 
the induced DA elevation in the NAc was attenuated, and the METH-induced CPP and 
hyperlocomotion were inhibited. 
PF11 is an ocotillol-type saponin that is isolated from American ginseng. Although it is still unclear 
that whether PF11 is transduced into the brain through the blood-brain barrier directly after oral 
administration, our study identified that treatment with PF11 antagonized the pharmacology of 
μ-opioid receptors by using behavioral tests. Moreover, repeated administration of PF11 increased 
extracellular GABA levels, and normalized METH-induced DA elevation in the NAc. As a result, the 
METH-induced CPP and locomotor sensitization were inhibited. 
Although both TMEM168 and PF11 reversed METH-induced DA elevation, the effects of them on 
GABA neurons in the NAc were opposite. Accumbal TMEM168 overexpression decreased 
extracellular GABA levels in the NAc, and this decreased GABA underlies the induced anxiety-like 
behaviors. On the other hand, repeated PF11 treatments increased extracellular accumbal GABA 
levels, and the elevated GABAergic neurotransmission indicated the inhibitory effect of PF11 on the 
METH-induced behaviors in mice. As GABA is an inhibitory neurotransmitter controlling 
dopaminergic neuronal activity, it seems a conflict that the inhibitory GABA was attenuated, and at 
the same time, METH-induced DA elevation was also attenuated in the NAc of the NAc-TMEM 
mice. However, extracellular GABA is not the only regulator for the dopaminergic system in the 
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NAc. The present study proved that the TEME168-induced OPN enhancement in the NAc was 
responsible for the inhibitory effects on METH in behavioral tests. It is suggested that the inhibitory 
mechanism of TMEM168 on METH might depend on the regulation of extracellular OPN, rather 
than the GABAergic changes in the NAc. The relationship between OPN and GABA is still unclear 
by now. We would like to confirm that whether OPN infusion affected accumbal GABA levels in 
near future. 
Despite PF11 has been proved as an effective inhibitor on METH-induced behavioral abnormalities; 
it would be an interesting investigation to furtherly study that whether the pharmacology of this 
compound is linked with the inhibitory mechanism of TMEM168-regulated OPN pathway. OPN is a 
ligand for integrin receptors, and it shows anti-inflammatory effects on neuronal system (Ailane et al., 
2013). PF11 also indicate neuroprotective effect in the brain (Li et al., 1999; Wu et al., 2003; Wang et 
al., 2013), and Toll-like receptor 4 (TLR4) is identified as a target of PF11 to exert 
anti-neuroinflammatory effect (Wang et al., 2014). Additionally, interactions between integrin 
receptors and TLR4 receptors have been reported in several studies (Ling et al, 2014; Zhang et al 
2002). Since the activation of integrin receptors indicates the influences on drug addiction (Wiggins 
et al. 2009; Wiggins et al. 2011), the studies mentioned above suggest a possibility of integrin 
signaling pathway that links the inhibitory functions of TMEM168 and PF11 on METH-induced 
dependence. This topic needs to be investigated in the future. 
In summary, TMEM168-regulated OPN system is a novel target pathway for the inhibition of 
METH-induced dependence, via regulating the dopaminergic function in the NAc. Additionally, PF11 
inhibits METH-induced CPP, locomotor sensitization, and accumbal extracellular DA elevation by 
regulating GABAergic neurons and μ-opioid receptors. Our studies may contribute to clarify the 
mechanism and develop new treatment of METH-induced dependence. 
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Figure 29 Integrin signaling pathway may suggest the inhibitory functions of TMEM168 and PF11 
on METH-induced dependence. This topic needs to be investigated in the future. 
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ABBREVIATIONS 
AAV adeno-associated virus 
ANOVA analysis of variance 
BDNF brain-derived neurotrophic factor 
CB cerebellum 
CMV cytomegalovirus  
CPP conditioned place preference 
CREB cAMP response element-binding protein  
DA dopamine 
DAMGO D-Ala
2
,N,Me-Phe
4
,Gly-ol
5
-enkaphalin 
DAPI 2-(4-amidinophenyl)-1H-indole-6-carboxamidine 
DARPP-32 dopamine- and cyclic AMP-regulated 
phosphoprotein of Mr 32,000 
DZP diazepam 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
FDA Food and Drug Administration 
GABA  γ-aminobutyric acid 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid 
HIP hippocampus 
HPLC high-performance liquid chromatography  
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IgG immunoglobulin G 
METH methamphetamine 
MMP matrix metalloproteinase 
NAc nucleus accumbens 
Nat8l N-acetyltransferase 8-like protein 
OPN osteopontin 
PBS phosphate-buffered saline 
PF11 pseudoginsenoside-F11  
PFA paraformaldehyde 
PFC prefrontal cortex 
PPI prepulse inhibition 
RGD arginine-glycine-aspartate 
RIS risperidone 
RT-PCR reverse transcription polymerase chain reaction 
S.E.M. standard error of the mean 
STR striatum 
SV40 poly A simian virus 40 polyadenylation  
TH  thalamus 
TLR4 Toll-like receptor 4 
TMEM168 transmembrane protein 168 
VEH vehicle 
VTA vental tegmental area 
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